Your browser is no longer supported. Please, upgrade your browser.
Settings
ALDX Aldeyra Therapeutics, Inc. daily Stock Chart
ALDX [NASD]
Aldeyra Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.58 Insider Own1.41% Shs Outstand27.19M Perf Week-4.60%
Market Cap321.66M Forward P/E- EPS next Y-1.98 Insider Trans0.00% Shs Float25.80M Perf Month30.00%
Income-29.40M PEG- EPS next Q-0.46 Inst Own60.00% Short Float2.98% Perf Quarter56.69%
Sales- P/S- EPS this Y14.80% Inst Trans-0.30% Short Ratio1.18 Perf Half Y69.00%
Book/sh1.87 P/B6.33 EPS next Y-10.60% ROA-66.20% Target Price30.14 Perf Year75.26%
Cash/sh1.53 P/C7.71 EPS next 5Y- ROE-74.20% 52W Range5.55 - 16.70 Perf YTD73.97%
Dividend- P/FCF- EPS past 5Y25.90% ROI- 52W High-29.16% Beta0.67
Dividend %- Quick Ratio8.10 Sales past 5Y- Gross Margin- 52W Low113.15% ATR1.01
Employees6 Current Ratio8.10 Sales Q/Q- Oper. Margin- RSI (14)53.34 Volatility7.34% 9.78%
OptionableYes Debt/Eq0.04 EPS Q/Q-30.60% Profit Margin- Rel Volume0.26 Prev Close11.92
ShortableYes LT Debt/Eq0.03 EarningsNov 08 BMO Payout- Avg Volume648.15K Price11.83
Recom1.60 SMA20-5.50% SMA5021.94% SMA20043.14% Volume170,632 Change-0.76%
Sep-26-18Reiterated Cantor Fitzgerald Overweight $23 → $30
Sep-13-18Initiated Janney Buy
Jan-26-18Initiated Seaport Global Securities Buy $13
Sep-26-16Initiated H.C. Wainwright Buy $18
Jul-01-16Initiated Stifel Buy $16
Jul-01-15Initiated Canaccord Genuity Buy $16
Mar-25-15Initiated Chardan Capital Markets Buy $16
Mar-20-15Reiterated H.C. Wainwright Buy $13 → $14
Nov-18-14Initiated H.C. Wainwright Buy $13
Jun-19-14Initiated Aegis Capital Buy $35
Oct-16-18 02:46PM  Research Report Identifies Aldeyra Therapeutics, AAON, Douglas Dynamics, Insmed, Northern Oil and Gas, and SMART Global with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Oct-02-18 09:32AM  Mangrove Partners: Performance, AUM, and Holdings Insider Monkey
Sep-28-18 10:06AM  Aldeyra Therapeutics (ALDX) Looks Good: Stock Adds 7.5% in Session Zacks
08:00AM  Aldeyra Therapeutics to Present at the 2018 Cantor Global Healthcare Conference PR Newswire
Sep-27-18 08:00PM  Aldeyra Therapeutics, Inc. Announces Public Offering of Common Stock PR Newswire +7.49%
09:12AM  Aldeyra Surges on Positive Dry Eye Study Data on Reproxalap Zacks
08:20AM  The Daily Biotech Pulse: Hologic Goes Shopping, Johnson & Johnson Snaps Ties With Geron Benzinga
08:00AM  Todays Research Reports on Stocks to Watch: Aldeyra Therapeutics and Alexion Pharmaceuticals ACCESSWIRE
Sep-26-18 04:01PM  Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock PR Newswire +34.85%
12:54PM  Aldeyra Therapeutics Stock Skyrockets on Dry Eye Study Results InvestorPlace
08:25AM  The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial Benzinga
08:12AM  Alderya's stock rockets after positive trial results of mesothelioma treatment MarketWatch
07:00AM  Aldeyra Therapeutics Announces Positive Results from Phase 2b Dry Eye Disease Clinical Trial PR Newswire
Sep-25-18 04:30PM  Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Results from Phase 2b Dry Eye Disease Clinical Trial PR Newswire
08:00AM  Aldeyra Therapeutics Announces Positive Mesothelioma Investigator-Sponsored Clinical Trial Results Presented at The International Association for The Study of Lung Cancer 19th World Conference on Lung Cancer PR Newswire
Sep-06-18 08:52AM  Implied Volatility Surging for Aldeyra Therapeutics (ALDX) Stock Options Zacks
Aug-17-18 08:20AM  Consolidated Research: 2018 Summary Expectations for PDF Solutions, MYOS RENS Technology, Aldeyra Therapeutics, The Ensign Group, Everi, and Ardelyx Fundamental Analysis, Key Performance Indications GlobeNewswire
Aug-09-18 07:30AM  Aldeyra Therapeutics Announces Second Quarter 2018 Financial Results and Provides Corporate Update PR Newswire
06:00AM  Aldeyra Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-02-18 08:00AM  Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second Quarter 2018 Financial Results and Corporate Update PR Newswire
Aug-01-18 08:00AM  Aldeyra Therapeutics to Present at the 38th Annual Canaccord Genuity Growth Conference PR Newswire
Jul-31-18 08:00AM  Aldeyra Therapeutics Appoints Joshua Reed as Chief Financial Officer PR Newswire
Jul-24-18 08:00AM  Aldeyra Therapeutics Announces First Patient Enrolled in Sjögren-Larsson Syndrome Pivotal Phase 3 Clinical Trial PR Newswire
Jul-12-18 08:00AM  Aldeyra Therapeutics Announces Last Patient Dosed in Dry Eye Disease Phase 2b Clinical Trial PR Newswire
Jun-26-18 08:00AM  Aldeyra Therapeutics Announces Development Programs at 2018 Research Day PR Newswire
Jun-25-18 04:01PM  Aldeyra Therapeutics Joins the Russell 3000® and 2000® Indexes PR Newswire
Jun-20-18 08:00AM  Aldeyra Therapeutics Announces 2018 Research Day PR Newswire
May-30-18 07:45AM  Analysis: Positioning to Benefit within Aldeyra Therapeutics, Freightcar America, Bank of Hawaii, Heritage-Crystal Clean, Amedisys, and U.S. Global Investors Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
May-15-18 07:30AM  Aldeyra Therapeutics Announces First Quarter 2018 Financial Results PR Newswire
06:00AM  Aldeyra Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-10-18 08:00AM  Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy PR Newswire
May-09-18 08:00AM  Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First Quarter 2018 Financial Results PR Newswire
May-01-18 07:00AM  Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results at the Association for Research in Vision and Ophthalmology 2018 Annual Meeting PR Newswire
Apr-24-18 08:00AM  Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial PR Newswire
Apr-19-18 07:50AM  Free Post Earnings Research Report: Curis Quarterly Revenue Jumped 38.10% ACCESSWIRE
Apr-05-18 08:15AM  Analysis: Positioning to Benefit within Euronet Worldwide, Innospec, Zosano Pharma, Ardelyx, Crown Castle International, and Aldeyra Therapeutics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Mar-29-18 07:30AM  Aldeyra Therapeutics Announces Year End 2017 Financial Results PR Newswire -7.98%
06:00AM  Aldeyra Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-22-18 04:28PM  Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Full Year 2017 Financial Results PR Newswire
Feb-27-18 08:00AM  Aldeyra Therapeutics Announces Agreement with Johnson & Johnson Innovation to Advance Novel Immune-Modulating Drugs for Systemic Inflammatory Diseases PR Newswire +12.34%
Feb-21-18 08:00AM  Aldeyra Therapeutics Selected for Podium Presentation of Phase 2a Dry Eye Disease Results at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting PR Newswire +5.63%
Feb-09-18 08:15AM  New Research Coverage Highlights Carter's, Invacare, Hortonworks, BGC Partners, Hyatt Hotels, and Aldeyra Therapeutics Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Jan-30-18 08:00AM  Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical Trial PR Newswire
Dec-14-17 03:55PM  Why Aldeyra Therapeutics Incs (NASDAQ:ALDX) CEO Pay Matters To You Simply Wall St.
Nov-29-17 08:00AM  Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data to the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting PR Newswire
Nov-09-17 01:05PM  Does Aldeyra Therapeutics Incs (ALDX) Debt Level Pose A Serious Problem? Simply Wall St.
07:30AM  Aldeyra Therapeutics Announces Third Quarter 2017 Financial Results PR Newswire
Nov-07-17 08:00AM  Aldeyra Therapeutics to Present at the Stifel 2017 Healthcare Conference PR Newswire
Nov-02-17 08:00AM  Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2017 Financial Results PR Newswire
Oct-25-17 08:00AM  Aldeyra Therapeutics Announces Presentation of Results on the Efficacy of ADX-102 in Noninfectious Anterior Uveitis at the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting PR Newswire
Oct-24-17 08:00AM  Aldeyra Therapeutics Presents Evidence for Aldehyde Sequestration as a Potential Therapeutic Approach in Succinic Semialdehyde Dehydrogenase Deficiency at the American Society of Human Genetics 2017 Annual Meeting PR Newswire
Oct-10-17 07:30AM  Aldeyra Therapeutics Announces New Data at 2017 Research & Development Day PR Newswire
Oct-05-17 08:00AM  Aldeyra Therapeutics Announces Presentation of Novel Data on the Efficacy of ADX-102 in a Model of Succinic Semialdehyde Dehydrogenase Activity at the 2017 American Society of Human Genetics Annual Meeting PR Newswire
Oct-02-17 07:12PM  Aldeyra Therapeutics Inc (ALDX): How Does It Impact Your Portfolio? Simply Wall St.
Sep-27-17 09:46AM  /C O R R E C T I O N -- Aldeyra Therapeutics, Inc./ PR Newswire
Sep-21-17 04:01PM  Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares PR Newswire
Sep-20-17 08:00AM  Aldeyra Therapeutics to Present at the Annual Cantor Fitzgerald Global Healthcare Conference PR Newswire
Sep-19-17 08:57AM  Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock PR Newswire -20.33%
Sep-18-17 04:01PM  Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock PR Newswire
02:04AM  [$$] Clinical Development News, Sept. 11-15 The Wall Street Journal
Sep-15-17 08:00AM  Today's Research Reports on Trending Tickers: Aldeyra Therapeutics and Arrowhead Pharmaceuticals ACCESSWIRE -17.59%
Sep-13-17 09:00AM  Aldeyra Therapeutics (ALDX) Soars: Stock Adds 34.5% in Session Zacks +12.39%
08:20AM  Today's Research Reports on Stocks to Watch: Aldeyra Therapeutics and Aethlon Medical ACCESSWIRE
Sep-12-17 09:32AM  Aldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers TheStreet.com +34.52%
08:24AM  Aldeyra Therapeutics' stock soars after positive results of dry eye disease treatment MarketWatch
07:00AM  Aldeyra Therapeutics Announces Positive Results from Dry Eye Disease Phase 2a Clinical Trial PR Newswire
Sep-11-17 04:30PM  Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Results from Dry Eye Disease Phase 2a Clinical Trial PR Newswire
Aug-08-17 07:30AM  Aldeyra Therapeutics Announces Second Quarter 2017 Financial Results PR Newswire -5.32%
05:00AM  Investor Network: Aldeyra Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-17 08:00AM  Aldeyra Therapeutics to Present at the 37th Annual Canaccord Genuity Growth Conference PR Newswire -5.38%
Aug-01-17 08:00AM  Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second Quarter 2017 Financial Results PR Newswire
Jul-18-17 08:00AM  Aldeyra Therapeutics Announces Last Patient Dosed in Dry Eye Disease Phase 2a Clinical Trial PR Newswire
Jun-19-17 08:00AM  Aldeyra Therapeutics to Present Novel Data on the Anti-Inflammatory Mechanism and Activity of ADX-102 at the World Congress on Inflammation 2017 Annual Meeting PR Newswire
Jun-14-17 10:05AM  US STOCKS-Wall St flat as banks fall after weak data; Fed eyed Reuters -8.82%
10:05AM  Aldeyra Stumbles Over Mid-Stage Clinical Results 24/7 Wall St.
09:36AM  Aldeyra Therapeutics stock drops 16% after mid-stage trial miss MarketWatch
06:50AM  Aldeyra Therapeutics Announces Results from Allergic Conjunctivitis Phase 2b Clinical Trial and Plans for Phase 3 Clinical Testing PR Newswire
Jun-13-17 04:30PM  Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Results from Allergic Conjunctivitis Phase 2b Clinical Trial PR Newswire
Jun-06-17 08:00AM  Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2a Clinical Trial PR Newswire
May-26-17 10:26AM  Roche (RHHBY) Presents Positive Data on IPF Drug Esbriet Zacks
May-25-17 07:23AM  Horizon (HZNP) Sells European Rights for Procysbi & Quinsair Zacks
May-23-17 04:06PM  Celgene (CELG) Multiple Sclerosis Drug Meets Primary Endpoint Zacks +5.75%
May-17-17 08:00AM  Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data at the Association for Research in Vision and Ophthalmology 2017 Annual Meeting Marketwired
May-15-17 07:30AM  Aldeyra Therapeutics Provides Corporate Update and Announces First Quarter 2017 Financial Results Marketwired +5.06%
07:00AM  Investor Network: Aldeyra Therapeutics, Inc. to Host Earnings Call Accesswire
May-08-17 08:00AM  Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Corporate Update and First Quarter 2017 Financial Results Marketwired
Apr-27-17 08:00AM  Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase 3 Clinical Trial Marketwired
Apr-20-17 08:00AM  Aldeyra Therapeutics, Inc. Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-102 in Sjögren-Larsson Syndrome Marketwired -16.35%
Apr-18-17 08:00AM  Aldeyra Therapeutics, Inc. Announces Last Patient Dosed in Allergic Conjunctivitis Phase 2b Clinical Trial Marketwired
Mar-30-17 08:08AM  ALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
08:00AM  Aldeyra Therapeutics Reports Full Year 2016 Financial Results Marketwired
07:07AM  Q4 2016 Aldeyra Therapeutics Inc Earnings Release - Before Market Open
Mar-22-17 08:00AM  Aldeyra Therapeutics Schedules Webcast and Conference Call for Full Year 2016 Financial Results Marketwired
Feb-28-17 08:00AM  Aldeyra Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference Marketwired
Feb-22-17 10:33AM  Executives at Crane Manufacturer Buy Shares Amid Optimism about Infrastructure Spending Boost, Plus Other Insider Trading Insider Monkey
10:33AM  Executives at Crane Manufacturer Buy Shares Amid Optimism about Infrastructure Spending Boost, Plus Other Insider Trading at Insider Monkey
08:00AM  Aldeyra Therapeutics Launches the Aldeyra Registry for Patients with Sjögren-Larsson Syndrome Marketwired
Feb-17-17 04:09PM  ALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:01PM  Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares Marketwired
Feb-14-17 06:11PM  ALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -5.06%
Aldeyra Therapeutics, Inc. engages in developing medicines for inflammatory diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase 2b clinical trial for the treatment of dry eye disease, as well as Phase 3 clinical trial for the treatment of noninfectious anterior uveitis. Its reproxalap is also in Phase 2b clinical trial for the treatment of allergic conjunctivitis, as well as Phase 2 clinical trial for the treatment of Sjogren-Larsson Syndrome. Its portfolio consists of ADX-1612, which inhibits heat shock protein 90 for the treatment of lymphoproliferative diseases; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 and ADX-103. Aldeyra Therapeutics, Inc. has a partnership agreement with Janssen to develop other RASP scavengers for immune-mediated diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.